Syros Pharmaceuticals Inc (NASDAQ:SYRS) registered an increase of 10.58% in shorted shares. In November was published SYRS’s total 1.51 million shorted shares by FINRA. Previously was reported up change of 10.58% from 1.37M shares. 19 days will cost SYRS with 80,100 average volume to restore its former position. Float short on Syros Pharmaceuticals Inc is 6.18%.
Ticker’s shares touched $7.36 during the last trading session after 4.91% change.Syros Pharmaceuticals, Inc. has volume of 107,280 shares. Since November 10, 2017 SYRS has declined 23.31% and is downtrending. SYRS underperformed the S&P500 by 38.93%.
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing treatments for cancer and immune-mediated diseases, and building a pipeline of gene control medicines.The firm is worth $247.70 million. The Company’s lead drug candidates are SY-1425, a selective RARa agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor with potential in a range of solid tumors and blood cancers.Currently it has negative earnings. The firm was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012.
A couple more Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) news were announced by: Seekingalpha.com which released on November 03, 2018 “Syros Pharmaceuticals, Inc. (SYRS) CEO Dr. Nancy Simonian on Q3 2018 Results – Earnings Call Transcript”, also Seekingalpha.com on November 05, 2018 announced “Morgan Stanley upgrades Teva and Bausch in premarket analyst action”, the next Businesswire.com is “Syros Announces Presentation of New Preclinical Data on SY-1365 in Treatment-Resistant HR-Positive Breast Cancer …” on November 09, 2018. Globenewswire.com has article titled “Market Trends Toward New Normal in Syros Pharmaceuticals, Westlake Chemical Partners LP, SITO Mobile …”.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.